Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

72.15
-2.0900-2.82%
Post-market: 72.150.00000.00%17:50 EDT
Volume:1.95M
Turnover:141.16M
Market Cap:11.92B
PE:-30.32
High:74.05
Open:74.00
Low:71.87
Close:74.24
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:0.70
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.80%
ROA:-7.31%
PB:24.37
PE(LYR):-30.30

Loading ...

Ionis names Peter Reikes to board as Lynne Parshall and Joseph Wender retire in 2026

Reuters
·
Mar 09

Ionis Announces Changes to Board of Directors

THOMSON REUTERS
·
Mar 09

Ionis EVP and Chief Scientific Officer C. Frank Bennett Disposes of Common Shares

Reuters
·
Mar 06

Metagenomi Therapeutics posts FY 2025 collaboration revenue of USD 25.2 million (-51.8%)

Reuters
·
Mar 06

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Mar 04

Ionis Pharmaceuticals (IONS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Mar 02

Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Simply Wall St.
·
Feb 28

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 28

Ionis Pharmaceuticals to present new DAWNZERA hereditary angioedema data at 2026 AAAAI Annual Meeting

Reuters
·
Feb 27

A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Large Estimated DCF Upside

Simply Wall St.
·
Feb 27

U.S. RESEARCH ROUNDUP-Cars.Com, Dell, Zscaler

Reuters
·
Feb 27

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN)

TIPRANKS
·
Feb 26

FDA accepts Ionis olezarsen sNDA for priority review in severe hypertriglyceridemia

Reuters
·
Feb 26

Ionis Pharmaceuticals Inc - FDA Has Set a Prescription Drug User Fee Act (Pdufa) Target Action Date of June 30, 2026

THOMSON REUTERS
·
Feb 26

Ionis Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Feb 26

Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum

TIPRANKS
·
Feb 26

Ionis Pharmaceuticals: Strong 4Q25 Beat and Catalyst-Rich 2026 Underpin Raised Buy Rating and $103 Target

TIPRANKS
·
Feb 26

Ionis Pharmaceuticals price target raised to $103 from $90 at Needham

TIPRANKS
·
Feb 26

Ionis Pharmaceuticals: Buy Rating Driven by Strong Q4 Beat, Growing Commercial Portfolio, and Pipeline Upside Catalysts

TIPRANKS
·
Feb 26

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)

TIPRANKS
·
Feb 25